Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease

Curated by Roxtron — RFID & NFC manufacturer. Visit roxtron.com

Pulnovo Medical has enrolled the first two U.S. patients in its clinical trial for the PADN radiofrequency ablation system, a device designed to treat pulmonary hypertension associated with left heart disease. This milestone signals a critical step toward FDA approval for a minimally invasive technology that addresses a high-volume patient segment currently lacking effective therapeutic options.